
    
      Based on the Ministerial Ordinance on Good Post-marketing Study Practice for Medical Device,
      the Surveillance will register patients with patent foramen ovale (PFO) who have experienced
      a PFO-related cryptogenic cerebral infarction (including diagnosed paradoxical cerebral
      embolism) or transient ischemic attack (determined by positive head imaging such as DWI) in
      whom an Amplatzer PFO Occluder implant was attempted (Marketing Approval No.
      30100BZX00024000, date May 28, 2019, hereinafter referred to as "PFO occluder").
    
  